Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  1990-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ard.49.6.354PMID 2143369PMCID PMC1004099
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dietary linoleic acid, gastric acid, and prostaglandin secretion.

  1988cited by this paper
• Peptic ulcer and non-steroidal anti-inflammatory agents

  1987cited by this paper
• Gastric mucosal protection with selective inhibition of thromboxane synthesis.

  1987cited by this paper
• An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa.

  1987cited by this paper
• Effect of indomethacin on gastric mucosal prostaglandins in humans. Correlation with mucosal damage.

  1987cited by this paper
• Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study.

  1987cited by this paper
• Etodolac compared with aspirin: an endoscopic study of the gastrointestinal tracts of normal volunteers.

  1986cited by this paper
• Measurement by radioimmunoassay of prostaglandins as their methyl oximes.

  1986cited by this paper
• Potent ulcerogenic actions of platelet-activating factor on the stomach

  1986cited by this paper
• Peptic ulcer and non-steroidal anti-inflammatory agents.

  1986cited by this paper
• Role of endogenous gastric prostanoids in the pathogenesis and therapy of duodenal ulcer.

  1986cited by this paper
• The stimulation of prostaglandin production by two antiprogesterone steroids in human endometrial cells.

  1986cited by this paper
• Synthesis of prostaglandin E2, thromboxane B2 and prostaglandin catabolism in gastritis and gastric ulcer.

  1986cited by this paper
• The influence of native porcine gastric mucus gel on hydrogen ion diffusion: the effect of potentially ulcerogenic agents

  1985cited by this paper
• Etodolac: effect on prostaglandin concentrations in gastric mucosa of rats.

  1985cited by this paper
• Duodenal mucosa synthesis of prostaglandins in duodenal ulcer disease.

  1985cited by this paper
• Focal gastric mucosal blood flow at the site of aspirin-induced ulceration.

  1985cited by this paper
• A new method for quantitation of ion fluxes across in vivo human gastric mucosa: effect of aspirin, acetaminophen, ethanol, and hyperosmolar solutions.

  1984cited by this paper
• Generation of prostaglandins in gastric mucosa of patients with peptic ulcer disease: effect of nonsteroidal antiinflammatory compounds.

  1984cited by this paper
• Gastroduodenal damage due to drugs, alcohol and smoking.

  1984cited by this paper
• A new method for quantitation of ion fluxes across in vivo human gastric mucosa: Effect of aspirin, acetaminophen, ethanol, and hyperosmolar solutions

  1984cited by this paper
• Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat

  1983cited by this paper
• Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat.

  1983cited by this paper
• Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat.

  1981cited by this paper
• Distribution of prostaglandins in gastric and duodenal mucosa of healthy subjects and duodenal ulcer patients: effects of aspirin and paracetamol.

  1981cited by this paper
• Temporal Relationship Between Cyclooxygenase Inhibition, as Measured by Prostacyclin Biosynthesis, and the Gastrointestinal Damage Induced by Indomethacin in the Rat

  1981cited by this paper
• Vasoconstriction with thromboxane A2 induces ulceration of the gastric mucosa

  1981cited by this paper
• Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa

  1980cited by this paper
• Cytoprotection by prostaglandins.

  1979cited by this paper
• INVESTIGATION OF THE VASODILATOR AND ANTISECRETORY ROLE OF PROSTAGLANDINS IN THE RAT GASTRIC MUCOSA BY USE OF NON‐STEROIDAL ANTI‐INFLAMMATORY DRUGS

  1975cited by this paper
• The role of copper in prostaglandin synthesis.

  1973cited by this paper
• The histological diagnosis of chronic gastritis in fibreoptic gastroscope biopsy specimens

  1972cited by this paper
• Permeability of the human gastric mucosa. Alteration by Acetylsalicylic acid and ethanol.

  1971cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Microwave synthesis of new naproxen analogues for chronic inflammation and their gastro-protective effect in post-operative model

  2026cites this paper
• Heterocyclic homoprostanoid derivative attenuates monoarthritis in rats: An in vitro and in vivo preclinical paradigm

  2018cites this paper
• Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury

  2015cites this paper
• Increased gastric mucus secretion alleviates non-steroidal anti-inflammatory drug-induced abdominal pain.

  2013cites this paper
• Reappraisal of its Pharmacology and Therapeutic Use in Rheumatic Diseases and Pain States

  2012cites this paper
• Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

  2008cites this paper
• Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.

  2007cites this paper
• Determinants of the short‐term gastric damage caused by NSAIDs in man

  2007cites this paper
• GI Risk and Risk Factors of NSAIDs

  2006cites this paper
• A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.

  2006cites this paper
• Large-scale open trials with etodolac (Lodine®) in France: An assessment of safety

  2005cites this paper
• Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.

  2005cites this paper
• Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins

  2005cites this paper
• Gastrointestinal effects of NSAIDs and coxibs.

  2003cites this paper
• Exploration in vitro et ex vivo du pouvoir inhibiteur des anti-inflammatoires non stéroïdiens vis-à-vis des iso-enzymes de la cyclooxygénase

  2002cites this paper
• Cyclooxygenase inhibition: between the devil and the deep blue sea

  2002cites this paper
• the deep blue sea Cyclooxygenase inhibition : between the devil and http : / / gut

  2002cites this paper
• NSAID toxicity: where are we and how do we go forward?

  2002cites this paper
• Etodolac (Lodine®): Profile of an established selective COX-2 inhibitor

  2001cites this paper
• COX-1 and COX-2 inhibitors.

  2001cites this paper
• Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.

  2001cites this paper
• COX-2 selectivity and inflammatory processes.

  2000cites this paper
• COX-2 inhibitors.

  1999cites this paper
• COX-2 inhibitors.

  1999cites this paper
• Clinical experience with cyclooxygenase-2 inhibitors

  1999cites this paper
• Overview of COX-2 in inflammation: from the biology to the clinic

  1999cites this paper
• Measurement of differential inhibition of COX-1 and COX-2 and the pharmacology of selective inhibitors.

  1999cites this paper
• Inhibition of cyclooxygenase-1 and cyclooxygenase-2 analysis of in vitro test systems and their clinical relevance.

  1998cites this paper
• Selective COX-2 Inhibitors

  1998cites this paper
• Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs

  1998cites this paper
• Scientific rationale for specific inhibition of COX-2.

  1998cites this paper
• Pathogenesis of nonsteroidal anti-inflammatory drug-related upper gastrointestinal toxicity.

  1998cites this paper
• The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs.

  1998cites this paper
• Differential inhibition of COX-1 and COX-2 by NSAIDs: a summary of results obtained using various test systems

  1998cites this paper
• A comparison of etodolac (Ultradol) with acetaminophen plus codeine (Tylenol #3) in controlling post-surgical pain in vasectomy patients.

  1997cites this paper
• Tissue selective inhibition of prostaglandin biosynthesis by etodolac.

  1997cites this paper
• NSAIDs revisited: selection, monitoring, and safe use.

  1997cites this paper
• Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy.

  1996cites this paper
• The Clinical Implications of Inhibition of the Inducible Form of Cyclo-Oxygenase

  1996cites this paper
• NSAIDs, gastrointestinal injury, and cytoprotection.

  1996cites this paper
• Protection from nsaid-induced gastrointestinal damage

  1995cites this paper
• Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double‐blind trial

  1995cites this paper
• NEW THERAPIES FOR RHEUMATOID ARTHRITIS

  1995cites this paper
• A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production.

  1995cites this paper
• A review on the strategies for the development and application of new anti-arthritic agents.

  1995cites this paper
• Gastric mucosal adaptation to etodolac and naproxen

  1995cites this paper
• Helicobacter pylori in duodenal and gastric ulcer disease.

  1995cites this paper
• Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study.

  1995cites this paper
• Interrelationships betweenHelicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease

  1994cites this paper
• Anti-inflammatory activity without NSAID-related gastropathy.

  1994cites this paper
• Predicting NSAID related ulcers--assessment of clinical and pathological risk factors and importance of differences in NSAID.

  1994cites this paper
• Helicobacter pylori and non-steroidal anti-inflammatory drugs: uncomfortable partners in peptic ulcer disease.

  1993cites this paper
• Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis.

  1993cites this paper
• Nonsteroidal anti-inflammatory drugs. Tailoring therapy to achieve results and avoid toxicity.

  1993cites this paper
• Double-blind comparison of etodolac sustained-release tablets and diclofenac sustained-release tablets in patients with rheumatoid arthritis: An interim report

  1993cites this paper
• Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs.

  1993cites this paper
• Gastrointestinal toxicity of newer NSAIDs.

  1993cites this paper
• Non-steroidal drug-induced peptic ulceration can we really protect the stomach?

  1992cites this paper
• Double-blind comparison of etodolac SR and diclofenac SR in the treatment of patients with degenerative joint disease of the knee.

  1992cites this paper
• Double-blind comparison of etodolac sustained-release tablets and piroxicam capsules in patients with rheumatoid arthritis: An interim report

  1992cites this paper
• Chemical gastritis and Helicobacter pylori related gastritis in patients receiving non-steroidal anti-inflammatory drugs: comparison and correlation with peptic ulceration.

  1992cites this paper
• Etodolac

  1991cites this paper
• Mechanisms of Gastric Mucosal Injury and Protection

  1991cites this paper
• Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.

  1991cites this paper
• Studies on prostaglandins, non-steroidal anti-inflammatory drugs, and Helicobacter pylori in peptic ulcer disease

  1990cites this paper
• Anti-inflammatory analgesics and drugs used in rheumatoid arthritis and gout

  1989cites this paper